{"version":"1.0","provider_name":"All About Cardiovascular System and Disorders","provider_url":"https:\/\/johnsonfrancis.org\/professional","author_name":"Johnson Francis","author_url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/","title":"Evinacumab: Angiopoietin-like protein 3 (ANGPTL3) inhibitor - All About Cardiovascular System and Disorders","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ujn9veUhL4\"><a href=\"https:\/\/johnsonfrancis.org\/professional\/evinacumab-angiopoietin-like-protein-3-angptl3-inhibitor\/\">Evinacumab: Angiopoietin-like protein 3 (ANGPTL3) inhibitor<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/johnsonfrancis.org\/professional\/evinacumab-angiopoietin-like-protein-3-angptl3-inhibitor\/embed\/#?secret=Ujn9veUhL4\" width=\"600\" height=\"338\" title=\"&#8220;Evinacumab: Angiopoietin-like protein 3 (ANGPTL3) inhibitor&#8221; &#8212; All About Cardiovascular System and Disorders\" data-secret=\"Ujn9veUhL4\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/johnsonfrancis.org\/professional\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2025\/07\/Evinacumab-Angiopoietin-like-protein-3-ANGPTL3-inhibitor.jpg","thumbnail_width":1200,"thumbnail_height":684,"description":"Angiopoietin-like protein 3 (ANGPTL3) is a protein synthesised by liver cells. It inhibits the expression lipoprotein lipase (LPL) gene. That will increase circulating triglycerides. Genetic activation of LPL gene can reduce triglycerides and is associated with low incidence of coronary artery disease and type 2 diabetes mellitus. Heterozygous loss of function mutations of ANGPTL3 are [&hellip;]"}